"It is our longstanding position that Amgen's patent claims are invalid and that the best interests of patients will be greatly disserved by an injunction preventing access to Praluent," Sanofi's Executive Vice President Karen Linehan said in a statement.
Amgen had sought the ban in an October 2014 lawsuit against Paris-based Sanofi and Tarrytown, New York-based Regeneron.
Amgen reported just $40 million in Repatha sales in the third quarter.
Reuters is the news and media division of Thomson Reuters.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms.